Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sanofi dengue vaccine...

    Sanofi dengue vaccine may worsen disease, company takes 120 million dollars hit

    Written by Ruby Khatun Khatun Published On 2017-11-30T14:09:54+05:30  |  Updated On 18 Aug 2021 3:30 PM IST

    PARIS: Use of Sanofi's dengue vaccine, the world's first approved shot against the mosquito-borne virus, is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infection.


    The French drugmaker said in a statement on Wednesday that as a result, it would book a charge in its fourth-quarter results of around 100 million euros ($118.57 million).


    Sanofi said it was writing to national regulatory agencies proposing that vaccination should not be recommended for individuals who have not been previously infected by dengue virus.



    This follows new analysis from six years of clinical data showing that Dengvaxia vaccine provides persistent protective benefit against dengue fever in those who had a prior infection.

    But for those not previously infected by the virus, more cases of the severe disease could occur in the long term following vaccination upon a subsequent dengue infection, Sanofi said.


    The company initially had high hopes for its dengue vaccine, touting it as a potential $1-billion-a-year-plus product, but initial sales last year were only 55 million euros and industry analysts have been dialing back expectations.


    Current consensus analyst forecasts point to annual sales of around 360 million euros for Dengvaxia by 2022, Thomson Reuters data shows.


    Although dengue is not as serious as malaria, it is spreading rapidly in many parts of the world. The virus kills about 20,000 people a year and infects hundreds of millions.


    While Sanofi's Dengvaxia is the first-ever approved vaccine for dengue, scientists already recognized it was not perfect and did not protect equally against the four different types of the virus in clinical tests.


    Japan's Takeda Pharmaceutical is developing a rival vaccine it hopes will perform better.


    Sanofi said the announcement was not affecting its full-year guidance of broadly stable earnings per share at constant exchange rates.




    (Reporting by Matthias Blamont, Ben Hirschler; Editing by Leigh Thomas)



    DengueDengue vaccineDengvaxiaFinancial resultsfourth quarterinfectionmosquito borne viruspharma newsSanofiscientistsvaccinationvaccine
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok